[Edaily Reporter KIM JI-WAN ] BL Pharmtech(065170)met with global pharmaceutical and biotech companies in Europe to discuss technology transfer and joint research on new drug candidates. The company plans to collaborate with an Institute for Basic Science (IBS) research unit and a liquid biopsy diagnostics company to elucidate the mechanism by which “ML-301” acts on cancer cells and to develop a clinical strategy for identifying patients expected to respond well to treatment.

ML-301 is a new drug development project based on an anti-cancer target, currently being advanced through Amgen’s Golden Ticket Program. The company has completed the initial lead compound discovery and efficacy validation in animal models and is preparing to enter the full-scale drug development phase.

According to BL Pharmtech on the 13th, the company held business meetings with multinational pharmaceutical companies, specialized research firms, and global investment firms during the 2026 Bio Europe event, which took place in Germany over three days from the 9th to the 11th, and discussed numerous concrete collaboration opportunities.

The most notable outcome was a meeting with BioNTech, a multinational pharmaceutical company based in Mainz, Germany. This company is known for winning the Nobel Prize in Physiology or Medicine for its development of mRNA vaccines. During the meeting, BL Pharmtech discussed joint research with BioNTech that would combine the core technologies of both companies.

Cooperation with Amgen also became more concrete. The two companies agreed to coordinate the practical arrangements for a visit by BL Pharmtech’s research team to Amgen’s U.S. headquarters next January, while also holding a specialized mentoring session with Amgen’s academic team to report on research progress to date and discuss future development directions.

The company also expanded its reach into next-generation drug development platforms and precision medicine. BL Pharmtech met with specialized companies possessing expertise in organoids and companion diagnostics to discuss collaborative research aimed at increasing clinical success rates.

The company also secured partnerships to target the Greater China market and advance its work in antibody engineering. It met with a leading Chinese investment firm—which had spearheaded major licensing deals for Korean biotech companies such as ImmuneOncia Therapeutics, Inc.—to discuss future technology transfer (L/O) strategies in China and plans to participate in next year’s “ChinaBio” partnering event.

Additionally, the company signed a non-disclosure agreement (NDA) with YUMAB, founded by Dr. Stefan Dubel of Germany, and agreed to continue strategic investment and collaboration on next-generation antibody development. Dr. Dubel is the author of a book on antibody engineering considered the “bible” of the antibody therapeutics field.

A BL Pharmtech official stated, “Through the three-day series of meetings in Europe, we reaffirmed the high level of interest in our pipeline and platform technology from the global market,” adding, “We will move forward swiftly not only with discussions on collaboration with big pharma companies such as BioNTech and Amgen but also with the identification of candidate compounds for ML-301, our key project, to generate tangible results.”